Results 61 to 70 of about 1,741 (166)

Tezepelumab: a promising therapy for severe uncontrolled asthma [PDF]

Exploration of Asthma & Allergy
Asthma is a complex inflammatory airway disease affecting a significant global population, spanning from childhood through adulthood. Despite advances in treatment modalities, a significant subset of patients, approximately 10%, grapple with severe ...
Argyri Klironomou, Georgia Papaiakovou, Agamemnon Bakakos, Nektarios Anagnostopoulos, Evangelia Koukaki, Efthymia Theofani, Maria Semitekolou, Nikoletta Rovina   +7 more
doaj   +1 more source

Efficacy and Safety of Biologic Therapies for Uncontrolled Asthma: An Overview of Systematic Reviews

Pediatric Pulmonology, Volume 61, Issue 7, July 2026.
ABSTRACT Background Asthma is a heterogeneous inflammatory disease that can cause substantial morbidity, reduced quality of life, and socioeconomic burden when uncontrolled. Biologic therapies have become central to the management of moderate‐to‐severe asthma by targeting specific inflammatory pathways.
Ronaldo José Faria, Patrícia Silva Bazoni, Jéssica Barreto Ribeiro dos Santos, Erica Tatiane da Silva, Michael Ruberson Ribeiro da Silva   +4 more
wiley   +1 more source

Contemporary Concise Review 2025: Asthma

Respirology, Volume 31, Issue 7, Page 693-701, July 2026.
ABSTRACT Asthma research in 2025 further advanced a multidimensional view of asthma, integrating disease trajectory, exacerbation risk, structural airway changes, comorbidities, and treatment responsiveness. In mild asthma, studies published in 2025 further reinforced the importance of anti‐inflammatory reliever strategies over SABA‐only treatment by ...
Jun Miyata, Koichi Fukunaga
wiley   +1 more source

Impact of Biologics on Oscillometry Defined Small Airway Dysfunction in Uncontrolled Asthma

Clinical &Experimental Allergy, Volume 56, Issue 7, Page 710-717, July 2026.
Forced oscillometry technique defined small airways dysfunction as a treatable trait in asthma. Monoclonal antibodies can improve small airways dysfunction, but their effects vary by mechanism of action. ABSTRACT Small airways dysfunction (SAD) is a recognised treatable trait within severe asthma, associated with worse symptom control and increased ...
Robert Greig, Philipp Suter, Rory Chan, Brian Lipworth   +3 more
wiley   +1 more source

Biologic Therapies: Targeting Severe Asthma at the Molecular Level

Journal of Education, Health and Sport
Introduction: Severe asthma is a chronic respiratory condition that affects a significant number of individuals, causing persistent inflammation of the airways and leading to recurrent symptoms such as wheezing, coughing, and shortness of breath ...
Kamila Szewczyk, Bartłomiej Szewczyk, Wiktoria Julia Krzesłowska, Paulina Pytel, Szymon Wiśniewski, Weronika Hołownia   +5 more
doaj   +1 more source

Evaluating the Potential Infectious Risk Profile of Biologics in Chronic Rhinosinusitis With Nasal Polyposis

International Forum of Allergy &Rhinology, Volume 16, Issue 7, Page 751-754, July 2026.
Maxime Fieux, Philippe Gevaert, Leigh J. Sowerby   +2 more
wiley   +1 more source

Tezepelumab improved chronic eosinophilic pneumonia in severe asthma patients with liver cirrhosis

Frontiers in Medicine
Systemic administration of corticosteroids is used in the treatment of chronic eosinophilic pneumonia (CEP). However, in patients with CEP as well as other comorbidities, the adverse effects of corticosteroids should be minimized as much as possible.
Mizuki Inaba, Yasuo Shimizu, Yasuo Shimizu, Yusuke Nakamura, Hiroaki Okutomi, Akihiro Takemasa, Akihiro Takemasa, Seiji Niho   +7 more
doaj   +1 more source

Real-life effectiveness of tezepelumab in severe asthma

Allergologia et Immunopathologia
Background: Tezepelumab is a human monoclonal antibody which inhibits the cytokine thymic stromal lymphopoietin and is effective in different asthma endotypes. Methods: This is a prospective, multicenter study of the Register of Severe Asthma of the Region of Murcia (RE-ASGRAMUR) Group performed under routine clinical practice conditions.
Juan Carlos Miralles-López, Francisco-José Bravo-Gutierrez, Rubén Andújar-Espinosa, Manuel Castilla-Martínez, Cayetano Díaz-Chantar, Mercedes Ramírez-Hernández, Sheila Cabrejos-Perotti, Maria Jesús Avilés-Inglés, Inmaculada Ibarra-Calabuig, Miguel Henrique Reyes-Cotes, Manuel José Pajarón-Fernández, Roberto Bernabéu-Mora, Consuelo Alcalde-Rumayor, María Loreto Alemany-Francés, José Valverde-Molina, Virginia Pérez-Fernández, null RE-ASGRAMUR GROUP   +16 more
openaire   +2 more sources

Tezepelumab Reduces Alarmin Cytokine Levels in Upper Airway Epithelial Cells in Patients With Severe Asthma

Clinical &Experimental Allergy, Volume 56, Issue 7, Page 830-832, July 2026.
Hazel Marriott, Adil Adatia, Subhabrata Moitra, Paige Lacy   +3 more
wiley   +1 more source

Tezepelumab for early-onset severe allergic asthma with persistent airflow limitation and small airway dysfunction: a treatable traits approach

Drugs in Context
We report the case of an 18-year-old woman with early-onset severe allergic asthma and no other type 2 biomarkers except the presence of IgE, complicated by persistent airflow limitation, air trapping and forced oscillation technique-defined small airway
Francesco Menzella, Claudio Sorino, Carlo Lombardi, Annamaria Bosi, Silvia Tonin, Lorenzo Corsi, Andrea Ballarin, Marcello Cottini   +7 more
doaj   +1 more source